BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

BioNTech and Regeneron are competing with rivals ... for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges ...

The validity of the patent is at the heart of patent litigation between CureVac and fellow German biotech BioNTech and its ... CureVac’s role in laying the scientific groundwork for those ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Scientific American covers the most important and exciting research, ideas and knowledge in science, health, technology, the environment and society. It is committed to sharing trustworthy ...

“Vote for Kamala Harris to Support Science, Health and the Environment,” read the headline in Scientific American on Monday, announcing the publication’s official support for the Democratic ...